WO2005123034A8 - Systemes de microparticules pour l'administration par voie orale de substances bioactives - Google Patents

Systemes de microparticules pour l'administration par voie orale de substances bioactives

Info

Publication number
WO2005123034A8
WO2005123034A8 PCT/IT2005/000353 IT2005000353W WO2005123034A8 WO 2005123034 A8 WO2005123034 A8 WO 2005123034A8 IT 2005000353 W IT2005000353 W IT 2005000353W WO 2005123034 A8 WO2005123034 A8 WO 2005123034A8
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
active substances
microparticulate systems
gastroresistant
oral administration
Prior art date
Application number
PCT/IT2005/000353
Other languages
English (en)
Other versions
WO2005123034A2 (fr
WO2005123034A3 (fr
Inventor
Daniele Vigo
Vincenzo Russo
Massimo Faustini
Mario Francesco Pace
Eleonora Munari
Maria Luisa Torre
Ubaldo Conte
Original Assignee
Univ Degli Studi Milano
Univ Pavia
Daniele Vigo
Vincenzo Russo
Massimo Faustini
Mario Francesco Pace
Eleonora Munari
Maria Luisa Torre
Ubaldo Conte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Milano, Univ Pavia, Daniele Vigo, Vincenzo Russo, Massimo Faustini, Mario Francesco Pace, Eleonora Munari, Maria Luisa Torre, Ubaldo Conte filed Critical Univ Degli Studi Milano
Priority to EP05760593A priority Critical patent/EP1778192A2/fr
Publication of WO2005123034A2 publication Critical patent/WO2005123034A2/fr
Publication of WO2005123034A8 publication Critical patent/WO2005123034A8/fr
Publication of WO2005123034A3 publication Critical patent/WO2005123034A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des systèmes de microparticules constitués d'une matrice polymère gastrorésistante, biocompatible et biodégradable contenant un polymère gastrorésistant et entérosoluble, un cryoprotecteur ou un lyoprotecteur, un sel de métal divalent ou trivalent d'un polymère biocompatible et biodégradable présentant des groupes acides et des substances bioactives. Lesdits systèmes de microparticules gastrorésistants sont utilisés pour l'administration, de préférence par voie orale, de substances bioactives à des espèces animales. La composition spéciale de ces systèmes à microparticules permet la protection desdites substances bioactives contre la dégradation par les protéases et l'acide gastrique, permettant leur libération dans l'intestin où leur action peut avoir lieu.
PCT/IT2005/000353 2004-06-22 2005-06-20 Systemes de microparticules pour l'administration par voie orale de substances bioactives WO2005123034A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05760593A EP1778192A2 (fr) 2004-06-22 2005-06-20 Systemes de microparticules pour l'administration par voie orale de substances bioactives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2004A001255 2004-06-22
ITMI20041255 ITMI20041255A1 (it) 2004-06-22 2004-06-22 Sistemi microparticellari per somministrazione orale di sostanze biologicamente attive

Publications (3)

Publication Number Publication Date
WO2005123034A2 WO2005123034A2 (fr) 2005-12-29
WO2005123034A8 true WO2005123034A8 (fr) 2006-03-30
WO2005123034A3 WO2005123034A3 (fr) 2006-09-14

Family

ID=35510243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2005/000353 WO2005123034A2 (fr) 2004-06-22 2005-06-20 Systemes de microparticules pour l'administration par voie orale de substances bioactives

Country Status (3)

Country Link
EP (1) EP1778192A2 (fr)
IT (1) ITMI20041255A1 (fr)
WO (1) WO2005123034A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082648A1 (fr) * 2007-12-21 2009-07-02 Inspiration Biopharmaceuticals, Inc. Formulations stabilisées de facteur ix contenant du tréhalose
JP5724108B2 (ja) * 2009-04-22 2015-05-27 メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ 凍結乾燥組成物
GB201102857D0 (en) 2011-02-18 2011-04-06 Danisco Feed additive composition
CN103429093A (zh) 2011-02-18 2013-12-04 杜邦营养生物科学有限公司 饲料添加剂组合物
GB201102865D0 (en) 2011-02-18 2011-04-06 Danisco Feed additive composition
WO2014020141A1 (fr) 2012-08-03 2014-02-06 Dupont Nutrition Biosciences Aps Composition d'additif alimentaire
GB201213801D0 (en) 2012-08-03 2012-09-12 Dupont Nutrition Biosci Aps Feed additive composition
US20160243154A1 (en) * 2013-10-23 2016-08-25 Donald W. Jessup Hyaluronic acid formulation
JP7177700B2 (ja) 2015-11-09 2022-11-24 デュポン ニュートリション バイオサイエンシス エーピーエス 飼料添加用組成物
JP6955497B2 (ja) 2015-12-29 2021-10-27 インターベット インターナショナル ベー． フェー． コクシジウム症ワクチン
CN113115952A (zh) * 2021-05-27 2021-07-16 江苏恒康生物科技有限公司 一种含微晶球的耐胃酸爆珠及其制备方法
US11833224B1 (en) 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960011236B1 (ko) * 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation

Also Published As

Publication number Publication date
WO2005123034A2 (fr) 2005-12-29
EP1778192A2 (fr) 2007-05-02
WO2005123034A3 (fr) 2006-09-14
ITMI20041255A1 (it) 2004-09-22

Similar Documents

Publication Publication Date Title
WO2005123034A8 (fr) Systemes de microparticules pour l'administration par voie orale de substances bioactives
WO2004035762A3 (fr) Polypeptides actifs du point de vue biologique a microencapsulation et liberation prolongee
WO2009036368A3 (fr) Vecteurs de médicament
WO2007067044A3 (fr) Capsules/comprimes contenant des principes actifs modifies
WO2006063350A3 (fr) Compositions et methodes destinees a traiter des affections de l'ongle
HK1115308A1 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2009073508A3 (fr) Compositions à base de gel de polysaccharide et procédés de libération prolongée de médicaments
EP2103306A3 (fr) Utilisation de un 5'-nucléotid pour la prévention/l'amélioration du trouble digestif fonctionnel
WO2007030266A3 (fr) Polymeres a liberation d'acide nitrique derives de polyimines modifiees
WO2006062845A3 (fr) Compositions a efficacite antivirale et antibacterienne elevee
MX2009004439A (es) Composicion de ibuprofeno.
WO2007070052A3 (fr) Compositions pharmaceutiques et méthodes destinées à traiter ou prévenir une maladie associée à l'oxalate
WO2008088030A1 (fr) Composition destinée à la prévention ou au traitement d'une maladie associée à un thrombus ou à un embole
HUS1900037I1 (hu) Orális mikrobaellenes gyógyszerészeti kompozíciók
WO2011016898A3 (fr) Compositions pesticides comprenant des adjuvants polymères
WO2005000268A3 (fr) Systemes d'administration de medicaments a liberation prolongee bioerodables
EP2153834A3 (fr) Compositions pharmaceutiques à libération prolongée comportant des sels de quétiapine
WO2008112390A3 (fr) Terpolymères pour libération régulée d'agents bioactifs par des dispositifs médicaux implantables
UA87471C2 (uk) Капсули, які містять пелети з діючими речовинами, які відрізняються між собою профілями вивільнення з них діючих речовин
MY148370A (en) Sustained-release composition and method for producing the same
WO2008070356A3 (fr) Copolymères séquencés biodégradables pour les dispositifs médicaux
WO2007017331A3 (fr) Systemes therapeutiques a liberation immediate pour une meilleure absorption par voie orale de la 7-[(e)]-t-butyloxyminomethyle] camptothecine
WO2007134158A3 (fr) Compositions de calcium
EP2801360A3 (fr) Utilisation de nicotine pour le traitement de saignement post-traumatique chez l'homme
WO2009139504A3 (fr) Formulation pharmaceutique solide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 52/2005 UNDER (72, 75) THE ADDRESS OF "RUSSO, VINCENZO" SHOULD READ "VIA LATTUADA, 20, I-20135MILANO" AND THE ADDRESS OF "PACE, MARIO, FRANCESCO" SHOULD READ "VIA MELOZZO DA FORL, 26, I-20060 MEDIGLIA"

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005760593

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005760593

Country of ref document: EP